BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Apogee Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Apogee Therapeutics's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06395948-1285@assetmemo.bio
DTSTAMP:20261121T005728Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Zumilokibart: Phase 2 readout est. (NCT06395948)
DESCRIPTION:Zumilokibart\, phase 2\, Atopic Dermatitis.\nStudy: A Study Eva
 luating APG777 in Atopic Dermatitis\nEstimated primary completion: Novembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/zumilokibart#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0639
 5948
URL:https://assetmemo.bio/drug/zumilokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07003425-1285@assetmemo.bio
DTSTAMP:20261121T005728Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Zumilokibart: Phase 2 readout est. (NCT07003425)
DESCRIPTION:Zumilokibart\, phase 2\, Atopic Dermatitis.\nStudy: A Long-term
  Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis\nEstimat
 ed primary completion: December 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/zumilokibart#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07003425
URL:https://assetmemo.bio/drug/zumilokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
